All In Biotech

NDA 212909 · Dr Reddys Labs SA

Biorphen

Phenylephrine Hydrochloride · Intravenous

Last checked: Nov 19, 2026Latest source record: Apr 12, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2019

Oct 21, 2019

Approved uses

2

Original approval plus efficacy supplements

Registered trials

627

74 Phase 3, 25 recruiting

FAERS reports

3,598

3,445 serious, 1,812 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Mar 31, 2026.

BIORPHEN is indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. BIORPHEN injection is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. ( 1 )

Mechanism: Phenylephrine hydrochloride is an α-1 adrenergic receptor agonist.

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Mar 11, 2021 Supplement 1 · Efficacy LabelLetter
  • Oct 21, 2019 Original approval · Type 5 - New Formulation or New Manufacturer LabelLetterReview
2 products under this application
  • BIORPHEN · PHENYLEPHRINE HYDROCHLORIDE 10MG/ML (10MG/ML) · SOLUTION, INTRAVENOUS · Discontinued
  • BIORPHEN · PHENYLEPHRINE HYDROCHLORIDE 0.5MG/5ML (0.1MG/ML) · SOLUTION, INTRAVENOUS · Prescription · TE AP

Clinical trials

Interventional ClinicalTrials.gov studies with "Phenylephrine" as an intervention, any sponsor and status, largest first.

All 627 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use1,363
  • pemphigus1,074
  • joint swelling1,038
  • pain1,004
  • maternal exposure during pregnancy1,003
  • infusion related reaction996
  • glossodynia995
  • rheumatoid arthritis993
  • drug ineffective984
  • pericarditis983
  • systemic lupus erythematosus981
  • wound966

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20042
200514
20066
200715
200815
20098
201043
201118
201252
201329
201416
201527
201628
201746
201846
201961
2020109
2021123
2022267
2023318
2024976
2025995
2026384

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part B: Biorphen (Phenylephrine HCL) · HCPCS J2372

2024 spending

$9K

Beneficiaries

1,827

1,849 claims

Per beneficiary

$5

2024 ASP limit $0.17 per unit

View as table
YearSpending
2020$0
2021$0
2022$0
2023$0
2024$8,844

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,178 on PubMed

Sponsor: Dr Reddys Labs SA

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.